Get started
Author

Amanda Polend

ORCID: 0000-0002-7640-5122
Observed ORCID: 0000-0002-7640-5122
OpenAlex ID: A5022840751
Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
2022 · Ulka N. Vaishampayan, Archana Thakur, et al. · Clinical Cancer Research · 34
PDF
Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate–Resistant Prostate Cancer
2024 · Elisabeth I. Heath, Archana Thakur, et al. · Cancer Research Communications · 9
Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
2025 · Ulka N. Vaishampayan, Archana Thakur, et al.
Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
2025 · Ulka N. Vaishampayan, Archana Thakur, et al.
Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
2025 · Ulka N. Vaishampayan, Archana Thakur, et al.
Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
2025 · Ulka N. Vaishampayan, Archana Thakur, et al.
Supplementary Table S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
2025 · Ulka N. Vaishampayan, Archana Thakur, et al.
Supplementary Table S1 from Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate–Resistant Prostate Cancer
2025 · Elisabeth I. Heath, Archana Thakur, et al.
PDF
Supplementary Table S3 from Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate–Resistant Prostate Cancer
2025 · Elisabeth I. Heath, Archana Thakur, et al.
Supplementary Figure S3A from Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate–Resistant Prostate Cancer
2025 · Elisabeth I. Heath, Archana Thakur, et al.
Supplementary Figure S3B from Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate–Resistant Prostate Cancer
2025 · Elisabeth I. Heath, Archana Thakur, et al.
Supplementary Figure S4 from Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate–Resistant Prostate Cancer
2025 · Elisabeth I. Heath, Archana Thakur, et al.
Supplementary Figure S1 from Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate–Resistant Prostate Cancer
2025 · Elisabeth I. Heath, Archana Thakur, et al.
Supplementary Figure S2 from Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate–Resistant Prostate Cancer
2025 · Elisabeth I. Heath, Archana Thakur, et al.
Supplementary Table S2 from Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate–Resistant Prostate Cancer
2025 · Elisabeth I. Heath, Archana Thakur, et al.
Supplementary Figure S3A from Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate–Resistant Prostate Cancer
2024 · Elisabeth I. Heath, Archana Thakur, et al.
Supplementary Figure S3A from Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate–Resistant Prostate Cancer
2024 · Elisabeth I. Heath, Archana Thakur, et al.
Supplementary Figure S3B from Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate–Resistant Prostate Cancer
2024 · Elisabeth I. Heath, Archana Thakur, et al.
Supplementary Figure S1 from Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate–Resistant Prostate Cancer
2024 · Elisabeth I. Heath, Archana Thakur, et al.
Supplementary Figure S2 from Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate–Resistant Prostate Cancer
2024 · Elisabeth I. Heath, Archana Thakur, et al.
Supplementary Figure S1 from Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate–Resistant Prostate Cancer
2024 · Elisabeth I. Heath, Archana Thakur, et al.
Supplementary Figure S2 from Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate–Resistant Prostate Cancer
2024 · Elisabeth I. Heath, Archana Thakur, et al.
Supplementary Table S3 from Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate–Resistant Prostate Cancer
2024 · Elisabeth I. Heath, Archana Thakur, et al.
Supplementary Table S2 from Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate–Resistant Prostate Cancer
2024 · Elisabeth I. Heath, Archana Thakur, et al.
Supplementary Table S3 from Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate–Resistant Prostate Cancer
2024 · Elisabeth I. Heath, Archana Thakur, et al.
Works count: 91
Citation count: 43
H-index: 2
I10-index: 1
Year
Topic
Type